Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Wsorking Party

Eolia Brissot*, Myriam Labopin, Domenico Russo, Sonja Martin, Christoph Schmid, Bertram Glass, Ron Ram, Zubeyde Nur Ozkurt, Jakob Passweg, Joan Hendrik Veelken, Donald Bunjes, Jane Apperley, Sebastian Giebel, Mohamad Mohty, Arnon Nagler

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Relapse of acute lymphoblastic leukemia (ALL) remains a major therapeutic challenge. Despite the consensus for proceeding to allogeneic stem cell transplantation (HSCT) in relapsing patients with ALL who achieve second complete remission (CR2) with salvage therapy, most patients lack a suitable matched-related histocompatible donor. The present multicenter retrospective study compared, for ALL patients in CR2, the HSCT outcome from all four possible alternative hematopoietic stem cell sources, namely matched unrelated 10/10 (n = 281), mismatched unrelated 9/10 (n = 125), haploidentical (n = 105), and cord blood (n = 104) donors. The 2-year outcomes were not statistically different between the four donor sources with respect to overall survival (38.3–47.2%), leukemia-free survival (30.5–39.6%), relapse incidence (32.6–37.6%), nonrelapse mortality (27.5–34.6%), and graft-versus-host disease-free relapse survival (21.4–33.1%). Donor choices for ALL patients achieving CR2 post first relapse are broad, ensuring that most patient in need secures a graft. Therefore, in practice, the donor choice should depend on timely availability and policy center.

Original languageEnglish
Pages (from-to)1763-1772
Number of pages10
JournalBone Marrow Transplantation
Volume55
Issue number9
DOIs
StatePublished - 1 Sep 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Wsorking Party'. Together they form a unique fingerprint.

Cite this